Case Reports in Pathology
Volume 2019 (2019), Article ID 4915086, 10 pages
https://doi.org/10.1155/2019/4915086

Case Report

Composite Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and T-Prolymphocytic Leukemia Presenting with Lymphocytosis, Skin Lesions, and Generalized Lymphadenopathy

Ali Sakhdari,¹ Guilin Tang,¹ Lawrence E. Ginsberg,² Cheryl F. Hirsch-Ginsberg,³ Carlos E. Bueso-Ramos,¹ L. Jeffrey Medeiros,¹ and Roberto N. Miranda¹

¹Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
²Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
³Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Correspondence should be addressed to Roberto N. Miranda; roberto.miranda@mdanderson.org

Received 25 November 2018; Revised 11 January 2019; Accepted 29 January 2019; Published 3 March 2019

Academic Editor: Cheryl Ann Palmer

Copyright © 2019 Ali Sakhdari et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in Western countries with an incidence of 3-5 cases per 100,000 persons. Most patients follow an indolent clinical course with eventual progression and need for therapy. In contrast, T-prolymphocytic leukemia (T-PLL) is a rare type of T-cell leukemia with most patients having an aggressive clinical course and a dismal prognosis. Therapies are limited for T-PLL patients and there is a high relapse rate. Morphologically, the cells of CLL and T-PLL can show overlapping features. Here, we report the case of a 61-year-old man who presented with a clinically indolent CLL and T-PLL, initially diagnosed solely and followed as CLL, despite the presence of an associated but unrecognized aberrant T-cell population in blood. After 2 years, the T-PLL component became more apparent with cutaneous and hematologic manifestations and the diagnosis was confirmed by immunophenotypic and cytogenetic analysis. Fluorescence in situ hybridization demonstrated an ATM deletion in both CLL and T-PLL components. Retrospective testing demonstrated that composite CLL and T-PLL were both present in skin and lymph nodes as well as in blood and bone marrow since initial presentation. This case is also unique because it highlights that a subset of T-PLL patients can present with clinically indolent disease. The concomitant detection of ATM mutation in CLL and T-PLL components raises the possibility of a common pathogenic mechanism.

1. Introduction

T-prolymphocytic leukemia (T-PLL) is a rare mature T-cell neoplasm that frequently presents with lymphocytosis, hepatosplenomegaly, lymphadenopathy, skin lesions, and serous effusions [1, 2]. The disease is most common in the elderly with a slight predilection for males [3]. Although most cases of T-PLL are clinically aggressive with frequent relapses, resistance to conventional chemotherapeutic modalities, and poor overall survival, a subset of patients with T-PLL initially present with a clinically indolent course [4, 5]. Cases of T-PLL show morphologic and immunophenotypic heterogeneity and therefore integration of clinicopathologic, laboratory, immunophenotypic, cytogenetics, and recently identified molecular features may be needed for proper discrimination from similar T-cell neoplasms that can present in leukemic phase [6, 7]. The introduction of anti-CD52 (alemtuzumab) in the frontline treatment of patients with T-PLL has dramatically increased the rate of complete remission (CR) and overall survival (OS) in this population, although most T-PLL patients ultimately relapse. Allogeneic or autologous stem cell transplantation may have a curative effect [8].

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is the most common chronic B-cell leukemia in Western countries with an incidence increasing with age [1, 9, 10]. Most patients with CLL/SLL follow an indolent clinical course and as many as two-thirds of patients do not need treatment at presentation. Untreated patients have a progressive accumulation of leukemic cells in the bone marrow and other lymphoid and nonlymphoid organs [11]. Eventually, symptomatic patients with high-stage disease need therapy at the time of diagnosis or soon after [12, 13]. In addition, immune phenomena are commonly associated with CLL/SLL, including autoimmune manifestations, immunodeficiency, opportunistic infections, and secondary neoplastic disorders [14–16]. Transformation to a more aggressive disease such as large B-cell lymphoma, or less frequently to other types of hematolymphoid malignancies, occurs in a small subset of patients [17–24]. More rarely, and after therapy, patients with CLL may develop a clonally unrelated T-cell lymphoma [22, 25, 26] or alternatively a histiocytic lineage neoplasm in a process called transdifferentiation, on which clonal relatedness can sometimes be demonstrated [27–29]. Herein we report the case of a 61-year-old patient who presented with composite CLL/SLL and T-PLL that was not recognized until the disease was advanced, and in retrospective analysis both disease components were present in different organ systems. Although similar cases have been rarely reported, herein we demonstrate with immunophenotypic markers and FISH probes in tissue sections that both disease components were together since initial presentation and propose a pathogenic mechanism based on the shared mutation of ATM gene mutation [30–32].

2. Case Presentation

A 61-year-old man was diagnosed with prostatic adenocarcinoma on routine work-up for nocturia and back pain in 2015, and a radical prostatectomy with a pelvic lymph node dissection was performed two months later. The lymph nodes were negative for metastatic prostate cancer but, however, showed partial effacement of the nodal architecture. Immunohistochemical studies performed on select lymph nodes showed nodular/follicular areas mainly composed of B-lymphocytes positive for CD20, CD5 (dim), CD23, and BCL2. These lymphocytes were negative for CD3, CD10, and cyclin D1. The interfollicular areas were almost entirely composed of T-lymphocytes expressing CD3, CD5 (bright), CD43, and BCL2. Interestingly, the pattern of CLL/SLL in the lymph node was unusual, as it seemed that the neoplastic cells were restricted to lymphoid follicles, a pattern known as the follicular pattern of CLL/SLL (Figures 1(a)–1(h)). A complete blood count showed a white blood cell (WBC) count of 12.5 × 10⁹/L and flow cytometry immunophenotypic analysis showed that 26% of blood cells had the following immunophenotype: CD20 (+), CD5 (+), CD19 (+), CD22 (+), CD23 (partial +), CD79b (+), CD200 (+) with surface immunoglobulin lambda light chain restriction, supporting a diagnosis of CLL/SLL.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

Figure 1: Composite chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and T-prolymphocytic leukemia (T-PLL). This lymph node shows partial effacement of the architecture by a vaguely nodular/follicular proliferation of small-to-medium-sized lymphocytes surrounded by a dense infiltrate of small-to-intermediate-size lymphocytes. Hematoxylin and eosin stain (a–c). Immunohistochemistry shows that the nodular/follicular areas react with the B-cell marker CD20 (d), whereas the interfollicular areas are highlighted with the T-cell marker CD3 (e, f). Note that the follicular areas are also faintly positive with CD5 (g) and dimly positive with CD23 (h), supporting CLL/SLL (h). This distribution of CLL/SLL centered on follicular dendritic cell meshworks highlighted with CD23 is extremely unusual and supports the so-called follicular pattern of CLL/SLL.

A referral report showed that conventional cytogenetic analysis revealed a complex karyotype and fluorescence in situ hybridization (FISH) screen for CLL/SLL revealed del(11q) and del(13q). Mutational status of the immunoglobulin heavy chain (IGH) revealed hypermutation of the variable region. The peripheral blood WBC doubling time was estimated at 6 months and hence was determined as not susceptible of chemotherapy. Mutational analysis using next-generation sequencing (NGS) 51-gene panel for hematologic neoplasms showed mutations in ATM and MDM2.

Due to the low-stage disease as determined by the lack of any major clinical or laboratory abnormalities, the patient was followed up with observation (“watch and wait”). At the time of initial diagnosis of CLL/SLL in early 2016, the patient noted a skin rash, mainly in the back with a waxing and waning clinical course (Figures 2(a) and 2(b)). Multiple skin biopsies were performed on these lesions diagnosed as superficial and deep dermis small T-cells and rare small lymphocytes with a periadnexal and perivascular distribution; a diagnosis of B-cell lymphoma was excluded (Figures 2(c)–2(g)). In one of these biopsy specimens, polymerase chain reaction- (PCR-) based assay to assess TRG revealed a small monoclonal T-cell population in a background of oligoclonal T-cells. PCR for IGH in the same specimens was consistently negative (Figures 2(a)–2(g)).

Figure 2: Annular erythematous maculopapular lesions on the upper and lower back (a, b). Dermal infiltration of small-to-medium-sized mature lymphocytes with periadnexal and perivascular distribution (c, d, e). These lymphocytes reacted predominantly with CD3 (f) and CD5 (not shown); only rare lymphocytes were positive for CD20 (g).

In August 2017, the patient developed anorexia, fatigue, headache, and drenching night sweats. The rash on his back increased in size while on topical treatment. The peripheral blood WBC count rose to 117 × 10⁹/L, compared with 12.5 × 10⁹/L at diagnosis (Figure 3(a)). A new staging computed tomography (CT) scan showed multicompartmental lymphadenopathy and splenomegaly (Figures 3(b) and 3(c)).

(a)

(b)

(c)

Figure 3: (a) Trending of WBC count from the time of diagnosis in January 2016 to the latest follow-up in March 2018. The arrow points to the WBC count at the time of bone marrow biopsy. It is noted that subsequent therapy led to leukopenia. (b) and (c) Computed tomography (CT) of mid-upper thorax shows multiple enlarged lymph nodes (arrows) in the mediastinum and axilla (b), while CT of the upper abdomen demonstrates a markedly enlarged spleen (arrow) (c).

The clinical diagnosis of progression of CLL/SLL was established and bone marrow aspiration and biopsy were performed before the initiation of planned therapeutic regimen of B-cell receptor inhibitor ibrutinib and anti-Bcl2 monoclonal antibody venetoclax. The biopsy specimen showed ~80% cellular bone marrow involved by three distinct aberrant cell populations: (a) T-PLL, representing ~70% of bone marrow cells, (b) minor population of CLL, representing 1.2% of bone marrow cells, and (c) CD5-negative small monotypic B-cells, representing 2.8% of bone marrow cells. The concurrent peripheral blood smear showed predominance of small-to-medium-sized lymphocytes with irregular nuclear contours, clumped chromatin, and conspicuous nucleoli (Figures 4(a)–4(g)).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

Figure 4: T-PLL in bone marrow biopsy specimen. A bone marrow clot section shows multiple lymphoid aggregates (white circle) composed predominantly of small-to-intermediate-size lymphocytes ((a), low power, (b), high power). The B-cell marker CD20 highlights scattered small lymphocytes (c). The T-cell marker CD3 highlights most lymphocytes in the lymphoid aggregates (d, e). Bone marrow aspirate smear shows numerous small-to-intermediate-size lymphocytes with scant cytoplasm displaying small projections and central nuclei with distinct nucleoli (f). The spectrum of T-PLL lymphocytes in the peripheral blood is shown (g); lymphocytes are predominantly small to intermediate in size with oval to slightly irregular nuclei and distinct nucleoli. The cell contours show blebs, while the cytoplasm is bluish and eccentric. Similar peripheral blood features were noted at initial presentation 3 years before.

Conventional cytogenetic analysis showed a complex karyotype: 40~45,X,-Y,add(3)(q29),-11,add(12)(p13),-13,inv(14)(q11.2q32),-15,der(15;22)(q10;q10),-16,-18,-19,-20,+6~10mar[cp3]/46,XY. FISH analysis showed TCL1 rearrangement and deletions of ATM, D13S319 locus, and LAMP1. Gene clonality assays showed both monoclonal TRB and IGH rearrangements. Amplicon-based targeted next-generation sequencing (NGS) assay performed using 28-gene panel on genomic DNA extracted from bone marrow aspiration showed ATM mutation (NM_000051.3(ATM):c.8078_8080del p.A2693del) at high frequency (variant allele frequency [VAF] of 28%) and MYD88 (NM_002468.4(MYD88):c.794T>C p.L265P) gene mutation at a very low frequency (VAF of <5%). Clinical and pathologic features of CLL/SLL and T-PLL as seen in our patient are summarized in Table 1.

Table 1: Summary of the most important clinical and pathologic features of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and T-cell prolymphocytic leukemia (T-PLL) as seen in our patient. Of note, these features do not necessarily represent the most common features of CLL/SLL or T-PLL.

Features
CLL/SLL
T-PLL

Initial presentation
Incidental enlargement of LN
(pelvic LN dissection)
Generalized and constitutional
symptoms

Immunophenotype
CD20+, CD5+, CD19+, CD23+, CD200+
CD3+, CD5+, CD7+, CD4+, CD8+, CD26+

TCL1 immunostain
Negative
Positive

IGH/T-cell gene rearrangements
Clonal IGH
Clonal TRB, TRG

Chromosomal and gene abnormalities
Trisomy 12
ATM deletion
inv(14)(q11.2q32)
ATM deletion,
TCL1 rearrangement

NGS analysis
NM_000051.3(ATM):c.8078_8080del p.A2693del
NM_002468.4(MYD88):c.794T>C p.L265P

The patient was diagnosed with composite T-PLL and CLL/SLL. The patient was started on alemtuzumab (total of 3 months of treatment with 30 milligrams 3 times weekly with continuous venous infusion) with excellent clinical and laboratory response showing reduction in size of mediastinal, hilar, axillary, abdominal, pelvic, and inguinal adenopathy. A substantial reduction in previous splenomegaly was observed (Figure 3).

In light of the new diagnosis of T-PLL, the diagnostic tissues from original pelvic lymph node, obtained at the time of prostatectomy and from one of the skin biopsy specimens, were reanalyzed with TCL1 immunostain to evaluate if T-PLL was present at the time of diagnosis of CLL (Figures 5(a)–5(d)). Both the lymph node and the skin biopsy specimens showed the presence of T-PLL cells highlighted by strong nuclear and cytoplasmic TCL-1 expression.

(a)

(b)

(c)

(d)

Figure 5: T-PLL involvement of lymph node (a, b) and skin (c, d). T-cells in the interfollicular areas are positive for TCL1 immunostain ((a), 200X and (b), 500X). T-cell aggregates in the dermis are positive for TCL1 ((c), 100X, (d), 400X). The insets in figure (c) show expression of CD3 (top) and lack of expression of CD20 (bottom) in neoplastic cells.

Flow cytometry immunophenotype of the bone marrow showed that 46% of analyzed cells were positive for CD3, CD7 (bright), and CD26. Also identified were two monotypic B-cell populations with 1.2% of total cells being CD5-positive and 2.8% of total cells being CD5-negative (Figures 6(a) and 6(b)).

(a)

(b)

(c)

(d)

Figure 6: Composite CLL/SLL and T-PLL. Flow cytometry immunophenotype ((a) and (b)) of a bone marrow aspirate specimen. Panel (a) shows a prominent T-cell population (CD5+, CD19-) as well as a minor CD19+/CD5+ B-cell population that corresponds to CLL/SLL. Panel (b) shows that 46% of the analyzed bone marrow cells were CD4+/CD8+ corresponding to T-PLL, as detected in 25% of T-PLL cases. This lymphocyte population also expressed CD7 (bright and homogenous) and CD26, further supporting the diagnosis of T-PLL. FISH analysis ((c) and (d)): (c) FISH analysis with ATM (green) and TP53 (red) exhibits 2 red, 1 green signal pattern, indicating ATM gene deletion; (d) FISH analysis with a TCL1 break-apart probe exhibits 1 red, 1 green (split), and 1 yellow signal, indicating TCL1 rearrangement.

FISH analysis was also performed on formalin-fixed paraffin-embedded pelvic lymph node to evaluate for rearrangements of TCL1 and ATM. TCL1 rearrangement was mainly seen in the interfollicular area (Figures 6(c) and 6(d)), whereas ATM was detected in both follicular and interfollicular areas. Therefore, TCL1 rearrangement was mainly confined to the T-cell component, while ATM deletion was detected in both the T-cell and B-cell components. Although desirable for a more definitive assessment of the mutations, cell sorting was not performed on analyzed specimens.

Figure 7 illustrates the chronological order of patient’s diagnoses and clinical management.

Figure 7: Timeline of most important pathologic findings from the diagnosis of prostate adenocarcinoma to T-PLL (abbreviations: BM: bone marrow, CLL: chronic lymphocytic leukemia, LAP: lymphadenopathy, LN: lymph node, PB: peripheral blood, Rx: treatment, SLL: small lymphocytic lymphoma, T-PLL: T-cell prolymphocytic leukemia, WBC: white blood cell count).

3. Discussion

CLL/SLL is the most common type of leukemia in Western countries [12, 33]. Although usually indolent, about 3-8% of CLL/SLL patients undergo transformation to a higher-grade lymphoma or leukemia, commonly to a diffuse large B-cell lymphoma, known as Richter transformation. It is also well recognized that patients with CLL/SLL have an increased risk of developing secondary malignancies likely due to underlying immunodeficiency or therapy [34, 35]. The distinction between true Richter transformation and the presence of a second, different lymphoid neoplasm (composite lymphoma) is not always apparent [36, 37]. The detection of clonal relationship between CLL and the higher-grade lymphoma supports Richter transformation [38]. More rarely, patients with CLL are followed by T-cell lymphoma or leukemia; however, in most of these cases, a clonal relationship was not shown [27, 28, 30, 39, 40].

On the other hand, T-PLL at the time of initial diagnosis is usually an aggressive neoplasm with rapid rising, high-level lymphocytosis, organomegaly, constitutional symptoms, and frequent laboratory abnormalities [1, 3, 41]. However, there is a subset of patients with T-PLL who present with a more indolent clinical behavior and moderate, relatively stable lymphocytosis [42–45]. Patients with indolent disease usually have a WBC of about 20 × 10⁹/L (range: 10-50 × 10⁹/L) and they have better overall survival compared to the aggressive forms [4, 5, 46]. A subset of patients with apparently indolent T-PLL subsequently manifest with an aggressive phase of disease with poor prognosis.

Herein we report a rare example of composite CLL/SLL and T-PLL. Composite lymphoma/leukemia of B-cell and T-cell lineage has been rarely noted in the literature [25, 39]. T-cell neoplasms reported as part of composite lymphoma (or possible transformation) with CLL/SLL have been of cytotoxic CD8⁺ T cell immunophenotype and we are unaware of any reports of cases similar to the case we report. Incidental CLL/SLL found in lymph nodes evaluated for other reasons is not an uncommon event [47–50]; however, the incidental finding of T-PLL is rare [4]. The presence of CLL/SLL in the dissected lymph node, though in a rare follicular pattern [51], in conjunction with a CLL/SLL clone in the peripheral blood, led to inadvertent failure to diagnose the concurrent T-PLL in the same lymph node. After the diagnosis of T-PLL, the patient was treated with standard protocol anti-CD52 monoclonal antibody (Campath) with complete morphological response and negative flow cytometric and molecular measurable minimal residual disease (MRD) for both T-PLL and CLL/SLL. As alemtuzumab is an efficient therapy for both T-PLL and CLL, this result is not unexpected and may likely be used in rare cases of composite leukemias [8, 52, 53].

Ideally the neoplastic cells of CLL and T-PLL should be analyzed separately, for example, after flow cytometry based-cell sorting, for underlying genetic and molecular abnormalities to unequivocally detect the possible initiation from common progenitor cells for both CLL and T-PLL cells. Subsequent albeit retrospective FISH analysis on FFPE pelvic lymph node showed that ATM deletion involved both the CLL/SLL and T-PLL areas, whereas TCL1 rearrangement was only detected in the interfollicular/T-PLL areas. These findings indicate that both CLL and T-PLL harbor ATM deletion and suggest that these two neoplasms could be derived from the same progenitor cells, a novel pathogenic mechanism in both neoplasms. This is in accord with a mechanistic role of ATM and ATM/TCL1 abnormalities in pathogenesis of CLL/SLL and T-PLL, respectively [44, 54]. While abnormalities involving ATM gene are seen in approximately 20% of CLL/SLL patients, the prevalence is much higher in T-PLL observed in over 80% of patients [44, 55].

In summary, we report a rare case of composite CLL/SLL and T-PLL that highlights the importance of careful histopathologic and immunophenotypic features of hematologic neoplasms with overlapping morphologic and immunophenotypic features. We also highlight the use of FISH in tissue sections that may complement routine immunohistochemical studies in defining the distribution of diseases with specific cytogenetic abnormalities such as ATM deletion and TCL1 translocation. Lastly, the recently noted high frequency of ATM mutations in T-PLL is of interest, another feature that overlaps with CLL/SLL.

Conflicts of Interest

The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.

References

S. H. Swerdlow, E. Campo, N. L. Harris et al., WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised, IARC, 4th edition, 2017.

K. Foucar, “Mature T-cell leukemias including T-prolymphocytic leukemia, adult T-cell leukemia/lymphoma, and sézary syndrome,” American Journal of Clinical Pathology, vol. 127, no. 4, pp. 496–510, 2007.

C. E. Dearden, “T-cell prolymphocytic leukemia,” Medical Oncology, vol. 23, no. 1, pp. 17–22, 2006.

R. Garand, J. Goasguen, A. Brizard et al., “Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia,” British Journal of Haematology, vol. 103, no. 2, pp. 488–494, 1998.

F. Cavazzini, A. Cuneo, A. Bardi, and G. Castoldi, “Indolent T-cell prolymphocytic leukemia: A case report and a review of literature,” American Journal of Hematology, vol. 74, no. 2, pp. 145–147, 2003.

A. Collignon, A. Wanquet, E. Maitre, E. Cornet, X. Troussard, and T. Aurran-Schleinitz, “Prolymphocytic leukemia: new insights in diagnosis and in treatment,” Current Oncology Reports, vol. 19, no. 4, p. 29, 2017.

K. Laribi, P. Lemaire, J. Sandrini, and A. B. de Materre, “Advances in the understanding and management of T-cell prolymphocytic leukemia,” Oncotarget , vol. 8, no. 61, pp. 104664–104686, 2017.

C. Dearden, “How I treat prolymphocytic leukemia,” Blood, vol. 120, no. 3, pp. 538–551, 2012.

J. A. Woyach, A. J. Johnson, and J. C. Byrd, “Chronic lymphocytic leukemia: Recent progress and current challenges,” Seminars in Oncology, vol. 43, no. 2, pp. 199-200, 2016.

C. S. Zent and N. E. Kay, “Chronic lymphocytic leukemia: Biology and current treatment,” Current Oncology Reports, vol. 9, no. 5, pp. 345–352, 2007.

M. Hallek, “Chronic lymphocytic leukemia: 2015 update on diagnosis, risk stratification, and treatment,” American Journal of Hematology, vol. 90, no. 5, pp. 446–460, 2015.

M. Hallek, “Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment,” American Journal of Hematology, vol. 92, no. 9, pp. 946–965, 2017.

J. R. Brown, “How I treat CLL patients with ibrutinib,” Blood, vol. 131, no. 4, pp. 379–386, 2018.

T. Tadmor, M. Welslau, and I. Hus, “A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia,” Expert Review of Hematology, vol. 11, no. 1, pp. 57–70, 2018.

U. Klein and R. Dalla-Favera, “New insights into the pathogenesis of chronic lymphocytic leukemia,” Seminars in Cancer Biology, vol. 20, no. 6, pp. 377–383, 2010.

S. Zhang and T. J. Kipps, “The pathogenesis of chronic lymphocytic leukemia,” Annual Review of Pathology: Mechanisms of Disease, vol. 9, pp. 103–118, 2014.

S. Yun, L. Zhang, M. R. Patel, T. C. Knepper, J. C. Chavez, and J. Pinilla-Ibarz, “Transformation of Chronic Lymphocytic Leukemia (CLL) into B-cell Acute Lymphoblastic Leukemia (ALL),” Blood, vol. 131, no. 11, pp. 1258–1261, 2018.

J. R. Krause, L. C. Drinkard, and L. C. Keglovits, “Hodgkin lymphoma transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma,” Baylor University Medical Center Proceedings, vol. 26, no. 1, pp. 16–18, 2013.

G. Fabbri, H. Khiabanian, A. B. Holmes et al., “Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome,” The Journal of Experimental Medicine, vol. 210, no. 11, pp. 2273–2288, 2013.

P. Jain and S. O'Brien, “Richter's transformation in chronic lymphocytic leukemia,” Oncology (Williston Park), vol. 26, no. 12, pp. 1146–1152, 2012.

E. Duchayne, G. Delsol, E. Kuhlein et al., “Hairy cell transformation of a B-cell chronic lymphocytic leukemia: A morphological, cytochemical, phenotypic and molecular study,” Leukemia, vol. 5, no. 2, pp. 150–155, 1991.

C. R. Fraser, W. Wang, M. Gomez et al., “Transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma to interdigitating dendritic cell sarcoma: Evidence for transdifferentiation of the lymphoma clone,” American Journal of Clinical Pathology, vol. 132, no. 6, pp. 928–939, 2009.

C. R. Kjeldsberg and J. Marty, “Prolymphocytic transformation of chronic lymphocytic leukemia,” Cancer, vol. 48, no. 11, pp. 2447–2457, 1981.

A. Pines, I. Ben-Bassat, G. Selzer, and B. Ramot, “Transformation of chronic lymphocytic leukemia to plasmacytoma,” Cancer, vol. 54, no. 9, pp. 1904–1907, 1984.

A. Lee, M. E. Skelly, D. W. Kingma, and L. J. Medeiros, “B-cell chronic lymphocytic leukemia followed by high grade T-cell lymphoma: An unusual variant of Richter's syndrome,” American Journal of Clinical Pathology, vol. 103, no. 3, pp. 348–352, 1995.

A. Novogrudsky, E. L. Amorosi, and S. R. S. Gottesman, “High-grade T-Cell lymphoma complicating B-Cell chronic lymphocytic leukemia: an unusual manifestation of Richter's Syndrome,” American Journal of Hematology, vol. 66, no. 3, pp. 203–206, 2001.

J. G. Strickler, T. W. Amsden, and P. J. Kurtin, “Small B-cell lymphoid neoplasms with coexisting T-cell lymphomas,” American Journal of Clinical Pathology, vol. 98, no. 4, pp. 424–429, 1992.

R. Küppers, U. Dührsen, and M.-L. Hansmann, “Pathogenesis, diagnosis, and treatment of composite lymphomas,” The Lancet Oncology, vol. 15, no. 10, pp. e435–e446, 2014.

A. L. Volk, S. A. Vannucci, W. Cook, K. A. Thompson, and C. M. Listinsky, “Composite mycosis fungoides and B-cell chronic lymphocytic leukemia,” Annals of Diagnostic Pathology, vol. 6, no. 3, pp. 172–182, 2002.

D. F. Boyer, N. I. Lindeman, N. L. Harris, and J. A. Ferry, “Peripheral T-cell lymphomas with cytotoxic phenotype in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma,” The American Journal of Surgical Pathology, vol. 38, no. 2, pp. 279–288, 2014.

A. Alomari, P. Hui, and M. Xu, “Composite peripheral T-cell lymphoma not otherwise specified, and B-cell small lymphocytic lymphoma presenting with hemophagocytic lymphohistiocytosis,” International Journal of Surgical Pathology, vol. 21, no. 3, pp. 303–308, 2013.

L. J. Medeiros and M. Stetler-Stevenson, “Composite B-cell and T-cell lymphoma: Coincidental occurrence or related neoplasms?” American Journal of Clinical Pathology, vol. 98, no. 4, pp. 387–389, 1992.

C. Nabhan and S. T. Rosen, “Chronic lymphocytic leukemia: a clinical review,” Journal of the American Medical Association, vol. 312, no. 21, pp. 2265–2276, 2014.

S. Molica, “Second neoplasms in chronic lymphocytic leukemia: Incidence and pathogenesis with emphasis on the role of different therapies,” Leukemia & Lymphoma, vol. 46, no. 1, pp. 49–54, 2005.

V. Callea, M. Brugiatelli, C. Stelitano, M. Gentile, F. Nobile, and F. Morabito, “Incidence of second neoplasia in patients with B-cell chronic lymphocytic leukemia treated with chlorambucil maintenance chemotherapy,” Leukemia & Lymphoma, vol. 47, no. 11, pp. 2314–2320, 2006.

M. Wetzler, R. Kurzrock, A. M. Goodacre, P. McLaughlin, S. Ku, and M. Talpaz, “Transformation of chronic lymphocytic leukemia to lymphoma of true histiocytic type,” Cancer, vol. 76, no. 4, pp. 609–617, 1995.

N. Jain and M. J. Keating, “Richter transformation of CLL,” Expert Review of Hematology, vol. 9, no. 8, pp. 793–801, 2016.

D. Rossi and G. Gaidano, “Richter syndrome: Molecular insights and clinical perspectives,” Hematological Oncology, vol. 27, no. 1, pp. 1–10, 2009.

A. Martinez, S. Pittaluga, N. Villamor et al., “Clonal T-cell populations and increased risk for cytotoxic T-cell lymphomas in B-CLL patients: clinicopathologic observations and molecular analysis,” The American Journal of Surgical Pathology, vol. 28, no. 7, pp. 849–858, 2004.

L. V. Abruzzo, L. M. Griffith, M. Nandedkar et al., “Histologically discordant lymphomas with B-cell and T-cell components,” American Journal of Clinical Pathology, vol. 108, no. 3, pp. 316–323, 1997.

J. R. Valbuena, M. Herling, J. H. Admirand, A. Padula, D. Jones, and L. J. Medeiros, “T-cell prolymphocytic leukemia involving extramedullary sites,” American Journal of Clinical Pathology, vol. 123, no. 3, pp. 456–464, 2005.

P. Jain, E. Aoki, M. Keating et al., “Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL),” Annals of Oncology, vol. 28, no. 7, pp. 1554–1559, 2017.

G. Hopfinger, R. Busch, N. Pflug et al., “Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia,” Cancer, vol. 119, no. 12, pp. 2258–2267, 2013.

A. Schrader, G. Crispatzu, S. Oberbeck et al., “Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL,” Nature Communications, vol. 9, no. 1, 2018.

F. Ravandi, S. O'Brien, D. Jones et al., “T-cell prolymphocytic leukemia: a single-institution experience,” Clinical Lymphoma, Myeloma & Leukemia, vol. 6, no. 3, pp. 234–239, 2005.

L. Soma, D. B. Cornfield, D. Prager, P. Nowell, and A. Bagg, “Unusually indolent T-cell prolymphocytic leukemia associated with a complex karyotype: Is this T-cell chronic lymphocytic leukemia?” American Journal of Hematology, vol. 71, no. 3, pp. 224–226, 2002.

P. J. Craig, J. E. Calonje, M. Harries, and C. M. Stefanato, “Incidental chronic lymphocytic leukaemia in a biopsy of Merkel cell carcinoma,” Journal of Cutaneous Pathology, vol. 36, no. 6, pp. 706–710, 2009.

R. J. Oviedo and A. A. Glickman, “Emergency splenectomy for trauma in the setting of splenomegaly, axillary lymphadenopathy, and incidental B-cell chronic lymphocytic leukemia: a case report,” International Journal of Surgery Case Reports, vol. 37, pp. 161–164, 2017.

A. J. Siddon and H. M. Rinder, “Pathology consultation on evaluating prognosis in incidental monoclonal lymphocytosis and chronic lymphocytic leukemia,” American Journal of Clinical Pathology, vol. 139, no. 6, pp. 708–712, 2013.

V. Rao, R. Watkins, A. Kaleem et al., “Leukaemic infiltration of gall bladder – unusual presentation of occult chronic lymphocytic leukaemia,” Journal of Surgical Case Reports, vol. 2011, no. 1, p. 7, 2011.

S. E. Gibson, S. H. Swerdlow, J. A. Ferry et al., “Reassessment of small lymphocytic lymphoma in the era of monoclonal B-cell lymphocytosis,” Haematologica, vol. 96, no. 8, pp. 1144–1152, 2011.

J. E. Arnason and J. R. Brown, “Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia,” Hematology-American Society of Hematology Education Program, vol. 2011, no. 1, pp. 119-120, 2011.

G. Lozanski, N. A. Heerema, I. W. Flinn et al., “Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions,” Blood, vol. 103, no. 9, pp. 3278–3281, 2004.

F. Bullrich, D. Rasio, S. Kitada et al., “ATM mutations in B-cell chronic lymphocytic leukemia,” Cancer Research, vol. 59, no. 1, pp. 24–27, 1999.

T. Stankovic and A. Skowronska, “The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia,” Leukemia & Lymphoma, vol. 55, no. 6, pp. 1227–1239, 2014.